Carmen Parks
Family · Corinth, MSNPI 1629186382
Payments from drug & device makers
Across 325 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AbbVie$676
- Novo Nordisk$650
- Lilly USA, LLC$385
- Abbott$372
- Mannkind Corporation$287
- plus $3K from 35 others
What the payments were for
- Travel & lodging$1,41820%
- Food & beverage$5,58080%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 26 | $2,080 |
| AbbVie | 35 | $676 |
| Novo Nordisk | 54 | $650 |
| Lilly USA, LLC | 35 | $385 |
| Abbott | 16 | $372 |
| Mannkind Corporation | 16 | $287 |
| Bayer | 15 | $262 |
| AstraZeneca | 11 | $261 |
| Sanofi-aventis U.S. LLC | 15 | $260 |
| Amgen | 15 | $241 |
| Xeris Pharmaceuticals, Inc. | 14 | $231 |
| Corcept Therapeutics | 9 | $162 |
| Dexcom, Inc. | 8 | $147 |
| Johnson & Johnson(2 entities) | 8 | $113 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $102 |
| Boehringer Ingelheim | 4 | $83 |
| Novartis | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $70 |
| Sequel Med Tech, LLC | 2 | $51 |
| GRT US Holding, Inc. | 3 | $47 |
| RGH Enterprises LLC | 1 | $39 |
| Insulet Corporation | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Urovant Sciences Inc | 2 | $34 |
| Lundbeck LLC | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Cequr Corporation | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Pfizer | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| CSL Behring | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Tris Pharma Inc | 1 | $15 |
| GSK | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Merck | 1 | $14 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,452
How this compares
$7,010 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 406 | $451,122 |
| FarxigaDapagliflozin Propanediol | 259 | $217,301 |
| Tresiba Flextouch U-200Insulin Degludec | 113 | $118,480 |
| MounjaroTirzepatide | 108 | $114,723 |
| JardianceEmpagliflozin | 123 | $103,431 |
| Xigduo XrDapaglifloz Propaned/Metformin | 79 | $74,419 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 58 | $71,000 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $65,421 |
| Humulin R U-500Insulin Regular, Human | 41 | $57,792 |
| TrulicityDulaglutide | 52 | $56,339 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 52 | $47,915 |
| JanuviaSitagliptin Phosphate | 43 | $44,755 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $42,421 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $41,123 |
| Novolog FlexpenInsulin Aspart | 111 | $33,950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $650 | $474,359487 claims |
| AstraZenecaFarxiga | $261 | $217,301259 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $385 | $176,606189 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy | $83 | $155,843185 claims |
| MerckJanuvia, Janumet Xr | $14 | $52,66655 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $260 | $47,91552 claims |
| Mannkind CorporationAfrezza | $287 | $23,60113 claims |
| AbbVieSynthroid | $676 | $2,35539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Corinth
- Phyllis FiveashCorinth$12K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.